Seeking Alpha

AstraZenica (AZN) chooses Charles River (CRL) as its partner for in vivo biology, which will...

AstraZenica (AZN) chooses Charles River (CRL) as its partner for in vivo biology, which will allow AZN to create a "flexible research platform." The deal is for three years and is expected to contribute approximately 1% to Charles Rivers' total net sales in 2013. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|